(GSFQ) is a specific Quality of Life (QoL) instrument which measures the impact of GERD symptoms on QoL. This study aims to adapt the GSFQ into Spanish (for Spain) culture and check the questionnaire psychometric properties. METHODS: An expert panel composed by a gastroenterologist, two methodologists, one expert in clinical research and one pharmacoeconomist supervised the adaptation process. The original instrument was translated and back-translated by two independent translators. For psychometric measures, a small sample was used to check the initial comprehension and factibility. A national representative sample was selected, stratified by gender, age (<45, Ն45 years) and GERD severity (0-I, ՆII, Savary-Miller score). Content validity was ensured by the original instrument. Cronbach's Alfa was used to assess reliability, and exploratory factor analysis to assess dimensionality. The EuroQol questionnaire and corresponding Visual analogue scales (VAS) were used for concurrent validity. RESULTS: A total of 3997 patients with pyrosis symptoms were recruited by 490 clinicians. Mean age was 49.35 (14.35) years and 48.4% were women. No ceiling or floor effects were detected in item responses. The reliability was good (0.864) and only 1 dimension exhibited an eigenvalue (3.45) above 1, explaining 58% of available variability. All items loaded on this dimension. Correlation were moderate but significant (p < 0.001) with EuroQol (0.499) and VAS (-0.481). The average score was 34.17 (19.685), in the 0-100 scale. Mean scores were significantly different between GERD diagnosed severity levels (F4,33035 = 84.9, p < 0.005), but no differences were found between Savary-Miller level IV and levels II-III. CON-CLUSION: The Spanish version of the GSFQ has good psychometric properties, behaves as a unidimensional scale, and is capable to discriminate between patients with varying degrees of GERD severity. Institut für Klinische Pharmakologie, Berlin, Germany OBJECTIVES: According to recently published guidelines, treatments effects on patient's health status should be measured by validated disease-specific Patient Reported Outcomes concepts. The aim of this study is to develop and validate a PRO questionnaire based on a conceptual framework for Crohn's disease. METHODS: An item pool of 77 items was generated through in focus groups and validated in a German sample (n = 104). Other data included the SF-36 and IBDQ. RESULTS: A principal component analysis revealed 7 independent factors: impact, intimacy, abdominal pain, bowel movements, nausea, extraintestinal problems and night sweat. The impact factor was shown to comprise further three interpretable domains: emotional, social, and physical. CONCLUSION: Symptoms and consequences of Crohn's disease need to be measured separately, since their constituent items do not load on the same factors. Further investigation could reduce the amount of items of one concept or find further items for relevant aspects such as problems with intimacy.
Institut für Klinische Pharmakologie, Berlin, Germany OBJECTIVES: According to recently published guidelines, treatments effects on patient's health status should be measured by validated disease-specific Patient Reported Outcomes concepts. The aim of this study is to develop and validate a PRO questionnaire based on a conceptual framework for Crohn's disease. METHODS: An item pool of 77 items was generated through in focus groups and validated in a German sample (n = 104). Other data included the SF-36 and IBDQ. RESULTS: A principal component analysis revealed 7 independent factors: impact, intimacy, abdominal pain, bowel movements, nausea, extraintestinal problems and night sweat. The impact factor was shown to comprise further three interpretable domains: emotional, social, and physical. CONCLUSION: Symptoms and consequences of Crohn's disease need to be measured separately, since their constituent items do not load on the same factors. Further investigation could reduce the amount of items of one concept or find further items for relevant aspects such as problems with intimacy.
PGI26 VALIDATED MEASURES OF HEALTH RELATED QUALITY OF LIFE AND PRODUCTIVITY IN A POPULATION OF PATIENTS REPORTING CHRONIC CONSTIPATION
Bolge SC 1 , Baran RW 2 1 Consumer Health Sciences, Princeton, NJ, USA, 2 Takeda Global Research and Development Center, Inc, Deerfield, IL, USA OBJECTIVES: To quantify the effects of chronic constipation on health-related quality of life, work productivity, and activity impairment. METHODS: Data are taken from the 2005 U.S. National Health and Wellness Survey, an annual cross-sectional study of the health care attitudes and behaviors of adults (age 18+). Chronic constipation sufferers are defined as experiencing chronic constipation in the past twelve months, and non-sufferers have not experienced chronic constipation. Respondents who experience inflammatory bowel disease or irritable bowel syndrome are excluded from the analysis. Quality of life is defined using the SF-8. The Work Productivity and Activity Impairment (WPAI) scale is used to quantify productivity loss. Linear regression models are used to control for potential confounders including demographics, number of physical comorbid conditions, and experiencing psychiatric comorbid conditions. RESULTS: The sample includes 1,288 (3%) chronic constipation sufferers and 35,676 (97%) non-sufferers. Chronic constipation sufferers have significantly worse mean physical (40.08 versus 48.79, p < 0.001) and mental (42.13 versus 49.75, p < 0.001) quality of life than non-sufferers. Controlling for potential confounders, constipation sufferers have SF-8 physical summary scores that are 3.550 (p < 0.001) points lower and SF-8 mental summary scores that are 2.891 (p < 0.001) points lower than non-sufferers. Among respondents employed full-time, chronic constipation sufferers have significantly greater productivity loss due to absenteeism (8.35 versus 3.10, p < 0.001), presenteeism (29.36 versus 13.36, p < 0.001), and overall (25.54 versus 12.18, p < 0.001). Controlling for potential confounders, constipation sufferers have greater absenteeism scores (3.102 points higher, p < 0.001), presenteeism scores (7.782 points higher, p < 0.001), and overall work productivity loss (6.017 points higher, p < 0.001) than non-sufferers. Chronic constipation sufferers also experience greater activity impairment (48.71 versus 21.75, p < 0.001) than non-sufferers, and have activity impairment scores 11.708 higher (p < 0.001) after controlling for potential confounders. CON-CLUSION: Chronic constipation has significant negative effects on physical and mental quality of life, work productivity, and activity impairment. Hospital Universitario Central de Asturias, Oviedo, Spain OBJECTIVES: To obtain the multi-attribute utility function (MAUF) for the Spanish version of the Short Form 6-D (SF-6D) and to compare utilities values with those determined by the British MAUF. To determine the weights of SF-36v1 items conforming the SF-6D instrument. METHODS: A whole-nation representative sample of 2,549 subjects [48.9% men, 48.5 (14.01) years] with mild to severe degree of Gastroesophageal Reflux Disease was recruited by 500 clinicians selected at random and used for this analysis. The Spanish versions of SF-6D and EQ-5D questionnaires plus the corresponding visual analogue scale were self-completed. Attribute weights were estimated using a catAbstracts A359 egorical regression model. First the estimation procedure was validated through estimation of the MAUF for the EQ-5D attributes based on the exiting Spanish tariff scores for the instrument. Secondly the MAUF for the SF-6D attributes was estimated regressed on the EQ-5D tariff scores. Weights were rescaled to yield scores ranging from worse possible state (0) to full health (1). RESULTS: All estimated attribute weights were significant and goodness of fit was reasonable (R2 = 0.799). Spanish utility values for the same health states are significantly different from those used in the UK; 0.7458 (0.208) vs. 0.7090 (0.143), p < 0.001. The shape of utility scores obtained with the Spanish MAUF exhibits a cubic pattern as compared to the British. Utilities obtained by the Spanish MAUF are higher for benign health states while severe states attain lower utilities. CONCLUSION: The proposed method allows for a valid and reliable estimation of a MAUF based on kwon utilities of a concurrent instrument, avoiding the need of incomplete designs to collect preferences. Evident differences between culture specific scoring systems encourage adapting instruments to the target culture in order to obtain valid measures. Spanish weights for SF-6D are now available to be used with existing or new SF-36v1 databases. , 2005) . This analysis evaluated the effect of CZP versus placebo on quality-adjusted life-years (QALYs) for each subject in these trials. METHODS: In PRECiSE 1, patients with active CD received double-blind CZP 400 mg (n = 331) or placebo (n = 328) every 4 weeks after induction. PRECiSE 2 began with an open-label induction period (CZP 400 mg at Weeks 0, 2 and 4). Patients who demonstrated a clinical response at Week 6 were randomised to receive CZP 400 mg (n = 215) or placebo (n = 210) every 4 weeks from Weeks 8 to 24. The EQ-5D was administered at each visit and converted into utility scores using an established algorithm (Dolan et al., 1995) . An estimate of QALYs was made for each patient from the area under the utility curve during the randomisation period of each trial. Mean QALYs and standard deviation (SD) were calculated by treatment group and compared using a Wilcoxon rank sum test. RESULTS: Over the 26-week PRECiSE 1 trial, the mean (SD) QALYs were 0.5456 (0.2993) for CZP and 0.4797 (0.3121) for placebo. Similarly, between Weeks 6 and 26 of PRECiSE 2, the mean (SD) QALYs were 0.4976 (0.2047) in the CZP group versus 0.4286 (0.2171) in the three injection followed by placebo group. A statistically significant gain in QALYs with CZP was observed in both trials: PRECiSE 1 0.0659 (p = 0.001); PRECiSE 2 0.0690 (p = 0.015). CONCLUSION: CZP improved both quality and quantity of remission and response period, as measured by QALYs, significantly more than placebo among patients with CD in two 26-week maintenance trials. AstraZeneca SA, Athens, Greece OBJECTIVES: Non-steroidal anti-inflammatory drugs (NSAIDs) and Aspirin are among the most widely used drugs, particularly for long-term treatment of arthritic disorders in primary care. Aspirin/NSAIDs cause upper-gastrointestinal symptoms. This study aimed to assess the nature and frequency of Upper-GI symptoms (GERD and/or Dyspepsia) experienced by patients receiving Aspirin and/or NSAIDs and to depict the current clinical practice in the field of gastroprotection of patients receiving these drugs. METHODS: A total of 1604 individuals (M/F: 743/861, age 58.37Ϯ13.1 years, BMI 27.5 Ϯ 3.7 Kg/m2) visiting 189 Primary Care Practitioners between June-July 2006 were included. A structured questionnaire was used to record demographic/medical history data including Aspirin/NSAIDs use, the antisecretory treatment received together with Aspirin/ NSAIDs and the presence of GERD (heartburn, regurgitation) and Dyspepsia (epigastric pain, early satiety, postprandial fullness) symptoms, which were based on widely accepted epidemiological criteria. RESULTS: The main indications for patients receiving Aspirin/NSAIDs were backache (16.7%), osteoarthritis (14.5%), coronary artery disease (8.9%) and rheumatoid arthritis (5.6%). Upper-GI symptoms (GERD and/or Dyspepsia) for Ն2 days/week were reported by 71.7% of participants. GERD was reported by 57.3% and Dyspepsia by 54.8% of participants, while 40.3% of them experienced symptoms of both diseases. Antisecretory treatment was used by 78.8% of participants (PPIs 75.8%, H2-antagonists 20.2%, Antacids 8.2%). Upper-GI symptoms of Ն2 day's per/week were reported by 70.5% of patients who received antisecretory treatment compared to 76.8% of those who did not (P < 0.025). Patients receiving PPI experienced upper-GI symptoms by 66.2%, significantly less compared to 83.9% of H2-antagonists/Antacids users (P < 0.001). CONCLUSION: Upper-GI symptoms are present in approximately 3/4 of Aspirin/NSAIDs users. Antisecretory treatment reduces Upper-GI symptoms, with PPIs being significantly superior than H2-antagonists/Antacids. However, in primary care, a substantial proportion of Aspirin/NSAIDs users remain symptomatic despite the use of antisecratory agents and therefore other parameters such as adherence to antisecratory treatment should be further investigated. To estimate demand and supply of blood products in Bavaria, as due to intransparency on prices and trade volumes reliable data are missing and to support optimal planning of blood supply and usage in Bavaria within the next two decades. METHODS: Data were collected through desk-top researches on demographics (e.g. Federal Statistical Office Germany, Bavarian State Office for Statistics and Data Processing), blood usage and donation behaviour in Germany (Robert Koch Institute, Paul-Ehrlich-Institute, Bavarian Red Cross) and
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